THE THREE LARGEST PROGRAM SERVICES ACCOMPLISHMENTS (AS MEASURED BY INVESTMENT SIZE) FOR THE FOUNDATION FIGHTING BLINDNESS RETINAL DEGENERATION FUND (FFB-RDF) DURING FISCAL YEAR 2024 WERE EQUITY INVESTMENTS IN OPUS GENETICS, OSANNI BIO, AND ATSENA THERAPEUTICS. OPUS GENETICS, ATSENA THERAPEUTICS AND OSANNI BIO ARE ALL CLINICALLY STAGED THERAPY COMPANIES. EACH OF THESE COMPANIES IS FOCUSED ON ADVANCING PROMISING THERAPIES FOR RETINAL DEGENERATIVE DISEASES.FISCAL 2024 SUMMARY:FFB-RDF INVESTED AN ADDITIONAL $1,449,835 IN OPUS GENETICS TO HELP ADVANCE ITS PIPELINE OF ORPHAN INHERITED RETINAL DISEASE GENE THERAPY INDICATIONS INCLUDING LCA5, BEST1, RHO, RDH12 AND MERTK. THE FIRST PATIENT WAS DOSED IN THE LCA5 PHASE I/II CLINICAL TRIAL IN AUGUST 2023. FFB-RDF INVESTED $2,807,443 IN ATSENA THERAPEUTICS TO SUPPORT THE ADVANCEMENT OF TWO CLINICALLY STAGED GENE THERAPY ASSETS FOR LCA1 AND XLRS, AND THE PRECLINICAL DEVELOPMENT OF GENE THERAPY ASSETS TOWARDS USH1B AND STARGARDT'S DISEASE. FFB-RDF INVESTED $3,000,000 IN OSANNI BIO TO SUPPORT THE ADVANCEMENT OF TWO CLINICALLY STAGED ASSETS AIMED AT REDUCING DRUSEN IN DRY AGE-RELATED MACULAR DEGENERATION AND GEOGRAPHIC ATROPHY.
